SWITZERLAND INNOVATION PARK INNOVAARE

Where Innovation Accelerates

Shaping the Future of Drug Discovery

塑造新药发现的未来






Keys and pathways to more precise medicine

获得更精准药物的关键和途径

Drug Discovery

新药发现

Content

目录

SWITZERLAND
INNOVATION
PARK INNOVAARE

Nils Gebhardt
Managing Director 总经理
PARK INNOVAARE

A perfect place for pharma and biotech companies!

成立药物和生物技术公司的理想之处!

Drug discovery has come a long way from crude extracts to pure chemicals, from guesswork to a structural and targeted approach to finding new and better remedies. To solve the riddle of a drug, to find the right target and to understand exactly how it influences processes at work in a human cell, scientists from many different fields have to work together: biologists, chemists, crystallographers, bioengineers, computer scientists, and even physicists and engineers. Their combined know-how is now bringing drug discovery into a new era.

PARK INNOVAARE, an innovation park at the Paul Scherrer Institute (PSI), is a preferred location for these types of collaboration. By utilizing large research facilities and specially developed methods, researchers can observe phenomena that have been unavailable up until now. For instance, with the new X-Ray Free Electron Laser (SwissFEL), recently put into operation at the PSI, scientists can see processes as fast as the vibrations of molecular bonds. It is an incredible step forward in basic research, or, as Professor Gebhard Schertler puts it in his interview, "With SwissFEL we are going to discover a new continent".

Since 2016, PARK INNOVAARE has been developing a focused innovation ecosystem providing access to all premises for state-of-the-art pharmacological research so that interdisciplinary collaborations between science and industry can flourish. Based on the unparalleled technological infrastructure of PSI and its more than 2,000 employees, a new breeding ground is in the making. The first companies have already begun to grow and flourish on this breeding ground.

为了获得更好的新药，新药发现经历了从粗提取到纯化学品，从猜测到结构性和针对性方法的漫长过程。为了解开药物之谜，找到正确的目标和准确了解它对人体细胞工作过程的影响，生物学家、化学家、结晶学家、生物工程师、计算机科学家，甚至物理学家和工程师等不同领域的众多专家学者必须携手合作。他们专业知识的大汇聚，正在将新药发现引向新纪元。

PARK INNOVAARE是保罗谢尔研究所（PSI）的创新园，是上述各类协作的理想之地。通过利用大型研究设施和专门开发的方法，研究人员可以发现迄今无法发现的现象。比如，借助X射线自由电子激光器（SwissFEL）最近在PSI投入使用，科学家可以观察到分子键振动这样快速的过程。这是基础研究方面一个令人难以置信的进步，正如Gebhard Schertler教授在采访中所说的："拥有SwissFEL，我们将可以发现新大陆"。

从2016年开始，PARKINNOVAARE建立重点创新生态系统，为最先进药理学研究提供必要的条件，使科学与行业之间的跨学科合作得以蓬勃发展。PSI拥有无与伦比的技术基础设施，员工超过2,000名。基于此，新的研发中心正在形成。在这里，第一批公司已经开发发展壮大。

In drug discovery, it's all about interaction

新药发现充满互动

Dr. John C. Reed
Head of Roche Pharma Research & Early Development
罗氏药物研究和早期开发部部长



Switzerland is Europe's biggest life sciences hub. It is the top location for biotechnological and pharmaceutical research. Tens of thousands of scientists, world-leading research institutions and more than 300 pharmaceutical and biotech firms form a remarkable life science cluster here. It is a living, constantly evolving ecosystem where all the elements are in dynamic interaction. Look at Roche: we work with partners at the local universities, such as the University of Basel and ETH in Zurich, at hospitals and at world-leading research institutions like the Paul Scherrer Institute (PSI). The network that this creates fosters the excellent exchange of ideas among scientists.

瑞士是欧洲最大的生命科学中心，位于生物技术和药物研究的顶级位置。数万名科学家、世界一流的研究机构和300多家制药和生物技术公司荟萃于此。这是一个充满活力、不断发展的生态系统，其中所有要素均为在动态互动。看看我们罗氏公司，我们与当地大学（如巴塞尔大学）、医院以及世界一流研究机构（如保罗谢尔研究所（PSI））的伙伴合作。他们不仅让我们接触到最聪明的科学思维，还提供我们使用最先进设施的机会。比如，PSI拥有SwissFEL等新型粒子加速器，处在世界领先地位。这样形成的网络，促进了科学家之间的思想交流，卓有成效。

Drug Discovery needs a cross-disciplinary approach

Today, these qualities are essential if we want to deliver highly innovative medicines and bring value to patients. It is why Roche is pursuing a globally decentralized pharmaceutical research strategy, conducting about 20% of its research and early development in Switzerland. For our open, interactive approach, we rely on a large, internationally diverse community of people with unique skill sets. In my experience, the magic happens when scientists from different disciplines work together on a task, and their fresh perspectives and know-how enable them to find creative solutions. We have witnessed many innovations in different fields and many of them have the

新药发现需要跨学科方法

今天，如果我们想提供高度创新的药物，为患者带来价值，这些特点必不可少。这就是罗氏采取将药物研究项目分散到全世界范围这一策略的原因所在，在瑞士开展的研究和早期开发仅占约20%。我们采用开放互动的方法，将全世界各领域众多具有独特技能的人聚集在一起。我本人经验之谈，当不同学科的科学家携手开展任务时，奇迹就会发生，他们新鲜的角度和诀窍令其找到创新性解决方案。我们见证了不同领域的许多创新，其中很多有可能在未来促进医疗保健系统的转变。随着个体化医学、大数据和高性能计算技术的兴起，新药发现不再是化学家和生物学家的自耕地，而是需要跨学科方法。

potential to transform the healthcare system in the future. With the rise of personalized medicine, big data, and high-performance computing technologies available today, drug discovery is no longer reserved for chemists and biologists, but requires a cross-disciplinary approach.

Switzerland — an outstanding destination for pharmaceutical research

Doing research in Switzerland offers huge opportunities for any pharmaceutical company eager to serve patients through innovation. Here, you will find not only a highly international community of excellent scientists but also political and economic stability, reliable legal and tax systems, and extraordinary quality of life for families. Switzerland is an outstanding destination for pharmaceutical research companies.

瑞士—药物研究的理想去处

对于渴望通过创新技术服务患者的制药公司，在瑞士开展研究可以拥有巨大的机会。在这里，您不仅见到高度国际化的优秀科学家团体，还享受政治经济稳定性、可靠的法律和税收制度以及非凡的家庭生活品质。瑞士不愧是药物研究公司的理想去处。

Professor Gebhard Schertler

Head of the Division of Biology and Chemistry at the Paul Scherrer Institute (PSI)

保罗谢尔研究所(PSI)生物化学系主任

"New era of pharmacology"

“药理学新纪元”

To develop new drugs, companies need to stay up to date about the latest discoveries in genomics, proteomics, structural and quantitative biology and learn how to translate this knowledge into a new product. Professor Gebhard Schertler shares his views on the challenges and opportunities of modern drug discovery and the role of basic research in it.

Professor Gebhardt Schertler is investigating G-Protein Coupled Receptors (GPCRs), the largest class of human receptors, at the Paul Scherrer Institute (PSI). He leads the Institute's Division of Biology and Chemistry, and he has established an interdisciplinary research group working on GPCRs using protein crystallography, electron microscopy, NMR, biophysics and bioinformatics. Professor Schertler has also had a key role in the foundation of several innovative biotech companies.

PARK INNOVAARE: What are the main challenges and opportunities in drug discovery today and what is your vision for the future?

Professor Schertler: The biggest opportunity of today's drug discovery is that we have more sources of information available for our R&D. We can obtain true pictures of how a drug binds to a molecule and identify the molecule's structure not only in one but in multiple states.

希望开发新药的公司必须掌握基因组学、蛋白质组学、结构和定量生物学的最新发现，并学会如何将这些知识转化为新产品。Gebhard Schertler教授就现代新药发现所面临的挑战和机遇以及其中基础研究所起的作用分享其观点。

Gebhard Schertler教授正在保罗谢尔研究所（PSI）研究G蛋白偶联受体（GPCRs），这是最大的人类受体类型。他担任该研究所生物化学系主任，建立了GPCRs跨学科研究团队，使用蛋白质结晶学、电子显微镜、NMR、生物物理学和生物信息学开展研究。Schertler教授还在几家创新型生物技术公司的创建起到关键作用。

PARK INNOVAARE: 当前新药发现的主要挑战和机遇是什么？您对未来有何展望？

Schertler 教授：目前新药发现的最大机遇，是我们的研发有更多可利用的信息来源。我们可以获得药物与蛋白分子结合的照片，解析多个状态下的分子结构。这些对于了解细胞内不同的信号意义重大。利用这些信息，可以更了解和如何避免副作用。我可以确定，我们正在步入新药发现的全新纪元，但复杂性也随之增多。

They are all relevant for understanding different signals in the cell. This information can then be used to better understand side effects and how to prevent them. I am certain we are entering a completely new age of drug discovery, but also face new complexity in drug discovery.

How can the pharmaceutical and biotech industry benefit from PSI's know-how and expertise in structural biology, protein biochemistry and biophysics?

It is not a single method or technology that we apply. At PSI, we have a multitude of expertise that we can bring together to find solutions for many challenges. Together, we can develop whole new technologies and methods. Thanks to this exchange and the translational potential that institutions like PARK INNOVAARE offer, we can push the borders of our present technological possibilities, which can lead to a paradigm shift.

PSI has just launched the X-Ray Free Electro Laser (SwissFEL). What role will it play in the future of drug discovery?

The launch of the SwissFEL marks a dramatic change in our ability to look at catalysis and processes of biomolecules. The brilliance increase from the synchrotron Swiss Light Source (SLS) to the SwissFEL is 10^9 — an incredible step forward. Thanks to large research facilities such as the SwissFEL, we can retrieve dynamic information at room temperature from biomolecules that bind ligands. This information can directly affect drug discovery chemistry, fostering faster ways to create lead compounds. What is important right now is for the industry to learn how to use this information.

What makes PSI and PARK INNOVAARE an ideal environment with respect to talent and hardware for a successful program in structure-based drug discovery?

What is particularly beneficial at this site is the outstanding combination of expertise of the Paul Scherrer Institute: we have a biology laboratory focusing on membrane proteins, and there is know-how in accelerator technologies, which makes room temperature crystallography possible. This combination, not commonly found anywhere else, opens multiple possibilities for companies to work on something unique.

制药和生物技术行业怎样才能从PSI在生物学、蛋白质生物化学和生物物理学方面的实用技能和专业知识中获益?

我们所应用的不是单项方法或技术。在PSI，我们拥有大量的专门知识或技能，我们可综合运用它们找到解决各种困难的方法。同时，我们可以开发出全新的技术和方法。有了PARK INNOVAARE等机构提供的交流机会和转化潜能，我们才能将我们现有技术可能性的边边缘往前推，这可以导致范例式的转变。

PSI刚刚推出X射线自由电子激光器(SwissFEL)。它将在新药发现的未来中起到什么作用?

SwissFEL的推出，标志着我们观察生物分子催化和过程的能力发生了显著的变化。SwissFEL的亮度是同步辐射Swiss Light Source (SLS) 的10^9倍—难以置信的飞跃。随着SwissFEL等大型研究设施的应用，我们可以在室温下从结合配体的生物分子中检索动态信息。这种信息会直接影响新药发现化学，产生合成先导化合物的更快方法。现在，行业应学会利用这种信息，这点很重要。

PSI和PARK INNOVAARE的人才和硬件环境非常优越，可使基于结构的新药发现计划得以成功实施，是什么促成了这一点?

这里特别有帮助的是保罗谢尔研究所各种专业知识和技能的出色组合：专门研究膜蛋白质的生物学实验室，以及使室温结晶学变成可能的加速器专业技术。这种组合在别处不多见，为公司提供了各种开展特色研究的机会。

Watch the complete interview at
登陆以下网址，可观看完整访谈过程
www.parkinnovaare.ch/drug-discovery



THE PAUL SCHERRER INSTITUTE (PSI)

is Switzerland's largest research center for natural and engineering sciences. It employs more than 2,000 people and, with more than 1,000 industrial contracts, has deep experience in collaboration with companies.

Brand new and nearly one of a kind:
X-RAY FREE ELECTRON LASER SWISSFEL

A winning technology:
ELECTRON MICROSCOPY FACILITY

Moving forward with drug discovery:
LABORATORY FOR BIOMOLECULAR RESEARCH

Open to industrial users:
SWISS LIGHT SOURCE (SLS)

PAUL SCHERRER INSTITUT PSI

Unique complex of large research facilities

HIGH EXPENDITURES in academic and industrial research as well as a network of world leading universities make Switzerland a preferred location for industrial R&D and cross-institutional collaborations.

Perfect innovation ecosystem

All you need to grow your business

- High R&D expenditures
- World class universities
- Thousands of pharma companies
- Business-friendly environment
- Lean administration
- Political stability
- Low taxes

ETH
EPFL
University of Basel

Pharmaceutical and biotech companies in Switzerland

BASF · Roche · Bayer · Novartis · Lonza · Cilag

PARK INNOVAARE is an integral part o
Innovation, the Swiss national network of inno
and as such is situated at the center of Europ
important pharma and biotech hub.



SWITZERLAND RANKS TOP when it comes to innovation. With its stable environment, it provides a perfect breeding ground for business development.

SHAPING THE FUTURE OF MODERN DRUG DISCOVERY

Switzerland and PARK INNOVAARE offer excellent opportunities for the global biotech and pharma industry

It takes 10 to 20 years from the idea to a new drug on the market and, on average, more than US$1 billion needs to be invested. The acceleration of drug discovery and development can have significant bottom-line effects. To improve these processes, it is critical to identify promising lead compounds. Structure-based drug discovery benefits from the outstanding technological possibilities provided by large research facilities. The unparalleled insights into the interaction of ligands with protein target molecules facilitate the identification and optimization of high-quality lead compounds – making these processes faster and increasing the probability that such compounds reach the market as a drug. PARK INNOVAARE, the innovation park at the Paul Scherrer Institute (PSI), provides access to one of the leading innovation ecosystems for the global biotech and pharma industry.

Modern R&D environment for biotech and pharma companies

SWITZERLAND INNOVATION PARK INNOVAARE

Dedicated modern drug discovery

Strong partner for industry

Cutting-edge research & analytical methods

Right in the middle of the vibrant campus of a world-leading institute

More than 36,000 m² of modern laboratories, clean rooms and conference facilities

EXPOSE

DECTRIS®*

CRYSTALLISE! Crystallization–X-ray–Structure

INTERAX Better Lead Molecules

Excelsus Structural Solutions

leadXpro

A COMMUNITY OF TECHNOLOGY LEADERS

and highly specialized service providers help you gain better insights into substances and processes

f Switzerland
ovation parks,
e's most

MANY

ZURICH

AUSTRIA

Advanced methods that can be applied on the spot

- Cryo-electron microscopy
- Single-Crystal X-Ray Diffraction (SC-RXD)
- Quantitative mathematical modelling
- Synchrotron X-Ray Powder Diffraction (SXRPD)
- Room temperature protein crystallography
- Serial crystal-lography
- X-ray diffraction on ultra-fast phenomena at the nanoscale

* DECTRIS is a global leader in HPC X-ray detectors for science and industry.

Unique set of skills and know-how

leadXpro

Unlock membrane proteins targets for better drug discovery
揭开膜蛋白靶标，提高药物发现效果

Founded 成立时间: 2015
Staff 员工数量: 10
Clients 客户: Heptares, Bayer, Boehringer Ingelheim, Axxam



Membrane protein drug targets represent a significant challenge for high-resolution 3D structure determination, limiting the discovery and development of novel medicines. Committed to unlocking more membrane protein targets, leadXpro AG masters the generation of purified proteins, applies biophysical methods and fully utilizes the Paul Scherrer Institute (PSI) facilities. The company has already identified novel ligand-bound GPCR structures with a great variety of binding modes.

膜蛋白药物靶标是高解像度三维结构测定的主要难题，限制了新药的发现和开发。leadXpro公司致力于发现更多的膜蛋白靶标，掌握纯蛋白生产技术，应用生物物理方法并充分利用保罗谢尔研究所(PSI)的设施。公司已经鉴定出新的配体结合GPCR结构，其中结合方式多种多样

InterAx
Better Lead Molecules

Biosensors technology platform for efficient lead discovery
构建生物传感器平台，有效发现先导化合物

Founded 成立时间: 2016
Staff 员工数量: 7
Clients 客户: international pharma and biotech companies
国际制药和生物技术公司

The effect a drug has on the human body depends on the chemical reactions its active substance activates in a cell. To understand this process, InterAx Biotech AG combines the output of protein-based IP-protected biosensors with the mathematical modelling of drug-induced GPCR (G Protein-Coupled Receptors) signaling pathways to identify safer and better drug candidates. This will help improve the selection of lead molecules.

药物对人体的效果取决于其活性成分在细胞内激活的化学反应。为了了解该过程，InterAx 生物技术公司将基于蛋白质的IP保护生物传感器输出与药物诱导的GPCR（G蛋白偶联受体）信号通路进行结合，鉴定出更安全、效果更好的候选药物。这将有助于改善先导分子的选择。

Excelsus Structural Solutions

Outstanding results with Synchrotron X-Ray Powder Diffraction
同步辐射X射线粉末衍射效果出色

Founded 成立时间: 2012
Staff 员工数量: 5
Clients 客户: Novartis Pharma, Cilag, Janssen Pharmaceutica, BASF, UCB Pharma

Excelsus Structural Solutions (Swiss) AG offers a fast and affordable access to state-of-the-art characterization tools for the structural and microstructural analysis of materials. Excelsus' core activities are based on the unique high-resolution, in-situ and time-resolved Synchrotron X-Ray Powder Diffraction (S-XRPD) method developed at the Paul Scherrer Institute (PSI). In addition, the Excelsus team was recently able to hit the lowest limit of detection (LoD) — 0.01 wt% (percentage per weight) — thus setting a new gold standard for XRPD.

Excelsus Structural Solutions（瑞士）公司为材料结构和微结构分析所需的最先进表征工具提供快速且价格合理的来源。Excelsus的核心活动基于独特的高解像度、原位、时间分辨同步辐射X射线粉末衍射（S-XRPD）方法。该方法由保罗谢尔研究所（PSI）开发。此外，Excelsus团队最近可以达到最低检测极限（LoD）—0.01 wt%（重量百分比）—因此为XRPD设定了新的金标准。

独特的专门知识和技能

Crystallization at its best – 最佳结晶效果

Founded 成立时间: 2014
Staff 员工数量: 2
Clients 客户: F-Hoffmann-La Roche, Vifor Pharma and further companies from the pharma, agro and chemical industries
以及制药、农业和化工行业的其他公司

Crystallise! AG focuses on the structural characterization of unknown or not fully characterized substances using single crystal X-ray analysis. It provides crystallographic services for the identification of small molecule compounds including the crystallization of the sample. Using state-of-the-art technologies at the Paul Scherrer Institute (PSI), the company has achieved unprecedented results in the absolute configuration determination of small single crystals of light atom compounds.

Crystallise! 公司专门从事未知物质或未充分表征物质的结构表征，所用方法为单晶X射线分析法。它为小分子化合物鉴定提供结晶学服务，包括样品结晶。该公司采用保罗谢尔研究所（PSI）的最先进技术，在轻原子化合物小单晶的绝对构型测定方面取得了前所未有的成果。

The data collection service at the Swiss Light Source
Swiss Light Source数据收集服务

Founded 成立时间: 2008
Staff 员工数量: 5
Clients 客户: international pharma and biotech companies
国际制药和生物技术公司

Expose GmbH is a spin-off company of the Paul Scherrer Institute (PSI), offering services and expertise in the field of X-ray protein crystallography to pharmaceutical and biotechnological companies. It includes: data collection and screening of protein and small molecule crystals at the Swiss Light Source (SLS), processing and analysis of the data, and protein structure solution and ligand refinement.

Expose公司是保罗谢尔研究所（PSI）的衍生公司，为制药和生物技术公司提供X射线蛋白结晶学领域的服务和专门知识和技能，包括Swiss Light Source（SLS）蛋白质和小分子晶体数据收集和筛选、数据处理和分析，以及蛋白质结构解析和配体精制。

Electron diffraction and new possibilities in drug discovery
电子衍射及新药发现中新的可能性

Founded 成立时间: 1988
Staff 员工数量: over 2,000
Clients 客户: Thousands of collaboration contracts with industry and other research institutions form all over the world
与行业及全球其他研究机构进行过数千次合作



Electron diffraction (ED) is a new approach to determining the structure of powders with only very few nanocrystals, unavailable for conventional techniques. With its advantages over SC-XRD and XRPD, electron diffraction represents one of the most promising fields of research for unlocking new possibilities in structure-based drug discovery. The Paul Scherrer Institute (PSI) operates an electron microscopy facility with the goal of making ED accessible to the pharmaceutical and biotechnological industries.

电子衍射（ED）是测定粉末结构的新方法。只需少量纳米晶体，传统技术无法做到这一点。与SC-XRD和XRPD相比，电子衍射技术具有其优势，可在基于结构的新药发现中发现新的可能性，是最有前途的研究领域之一。保罗谢尔研究所（PSI）拥有电子显微镜设备，其目标是ED在制药和生物技术行业得以应用。

Innovation ecosystem for leading pharma and biotech research

药物和生物技术前沿研究的创新生态系统

Paul Scherrer Institute (PSI): Life Science basic research on the top level

The Paul Scherrer Institute (PSI) is Switzerland's biggest research institute for natural and engineering sciences, employing more than 2,000 people. It hosts most of the country's large research infrastructures, including the synchrotron Swiss Light Source (SLS) and, most recently, the Swiss X-Ray Free-Electron Laser (SwissFEL). The Institute provides perfect conditions for basic and translational biological research and has an extraordinary track record of collaborations with industry, boasting more than 1,000 contracts.

The PSI Division of Biology and Chemistry hosts the Laboratory of Biomolecular Research (LBR), which works on three broad, overlapping topics:

- membrane protein structure and function
- structure-functional relationships of macromolecular assemblies of the cell
- new methods for structural analysis of biomolecules.

The laboratory is exceptionally well equipped. It hosts extensive biophysical instrumentation and an electron microscopy facility. LBR strongly benefits from the on-site interaction with the large research facilities at PSI.

保罗谢尔研究所（PSI）：顶级生命科学基础研究

保罗谢尔研究所（PSI）是瑞士最大的自然与工程科学研究机构，员工人数达2,000以上。它拥有大部分瑞士的大型研究基础设施，包括同步辐射Swiss Light Source（SLS）和新近推出的瑞士X射线自由电子激光器（SwissFEL），后者全球数量有限。研究所为生物学基础和成果转化研究提供良好的环境，在与行业合作方面具有非凡的记录，合作数量已突破1,000次。

PSI生物化学系拥有生物分子研究实验室（LBR），其研究包括三个广泛且重叠的主题

- 膜蛋白质结构和功能
- 细胞大分子组装结构与功能关系
- 生物分子结构分析新方法

实验室装备精良，拥有大量的生物物理仪器和一台电子显微镜设备。LBR从与PSI大型研究设施现场互动中受益非浅。

在PSI所开展的膜蛋白质研究，可为新药发现开辟新途径。比如，在LBR进行的一项重大研究涉及G蛋白偶联受体（GPCR）。“目前，30%以上药物的靶标是这组蛋白质。”生物化学系主任Gebhard Schertler教授如此说。研究所与行业开展联合项目。

The research conducted at PSI on membrane proteins can open up new ways for better drug discovery. For example, one major research focus at LBR is the field of G Protein-Coupled Receptors (GPCR). "Over 30% of today's drugs target this group of proteins," explains Professor Gebhard Schertler, Head of the Division Biology and Chemistry (BIO). Researchers at LBR are also partners in industry collaborations in a number of fields in drug discovery.

PARK INNOVAARE: Infrastructure and R&D solutions for pharma and biotech

One of the most crucial factors for young companies — as well as for the R&D units of large enterprises — is accessible, state-of-the-art lab and office space. Located in close proximity to the Paul Scherrer Institute (PSI), PARK INNOVAARE provides the best possible operating conditions for biotech and pharmaceutical companies engaged in early-stage drug discovery. This includes the availability of modern laboratories and office space.

PARK INNOVAARE will offer companies a combination of shared and private lab and office space, as well as value-added solutions including operational support, education programs and business services. As such, PARK INNOVAARE supports an open-innovation, no-strings-attached approach.

Switzerland Innovation: the national network of innovation parks

As a network of five innovation parks, Switzerland Innovation provides a platform where corporate research and development teams can collaborate with leading scientists, industry partners and pioneering start-ups.
It facilitates access to the expertise of the world's leading universities, such as Swiss Federal Institutes of Technology ETH Zurich and EPFL, and the Paul Scherrer Institute (PSI). Resident companies benefit from effective technology transfer platforms, state-of-the-art infrastructure and a unique atmosphere, which together foster the creation of the next best-selling products and services.

PARK INNOVAARE: 制药和生物技术的基础设施和研发解决方案

决定年轻公司以及大型企业研发单位的最关键因素之一，是最先进实验室和办公空间的使用途径。PARK INNOVAARE的位置靠近保罗谢尔研究所，为从事早期新药发现的生物技术和制药公司提供最佳操作条件，其中包括现代实验室和办公空间的可利用性。

PARK INNOVAARE为公司提供共享和私人实验室及办公场所，以及增值的解决方案，包括运营支持、教育项目和商业服务。因此，PARK INNOVAARE支持开放创新、没有任何附加条件的方法。

瑞士创新: 国家创新园网络

瑞士的创新园网络包括五个创新园，为企业研究和开发团队提供了一个平台，他们可以通过这个平台，与首席科学家、行业合作伙伴以及新创业公司合作。它有助于获取世界一流大学，比如瑞士联邦理工学院、瑞士洛桑联邦理工学院以及保罗谢尔研究所等的专业知识和技能。常驻公司可受益于有效的技术转让平台、最先进基础设施和独特的氛气氛，这些都为最热销产品和服务的诞生创造了良好的条件。

What will biotech and pharmaceutical companies find in Switzerland and at PARK INNOVAARE?

生物技术和制药公司将在瑞士和PARK INNOVAARE发现什么?

Switzerland is Europe's biggest life sciences hub and the top location for biotechnological and pharmaceutical research. Thousands of scientists, world-leading research institutions such as ETH Zurich, University of Basel, or the Paul Scherrer Institute (PSI), and more than 1,500 companies in the life science sector form a unique innovation ecosystem which is among the top pharma clusters worldwide. PARK INNOVAARE is a perfect entry point into this ecosystem.

Who should consider PARK INNOVAARE for relocation?

PARK INNOVAARE is a primary location for those who want to improve the early phases of the drug development process. The unique complex of large research facilities operated by the Paul Scherrer Institute (PSI) is one of a kind and allows unprecedented insights into the structure of molecules and the way they interact. A community of specialized service providers supports pharma and biotech companies in getting the best out of their samples and are reliable research partners.

How to start a relocation process?

Just contact us! Once we understand your needs, we will put you in touch with leading scientists or corporate decision makers in the respective field and help you discover the existing opportunities at the site. We also collaborate with specialists from local promotion agencies advising on tax and legal matters.

Where can I learn more about the existing opportunities in Switzerland?

Switzerland has a highly service-oriented foreign trade promotion organization, Swiss Global Enterprise (S-GE), with Swiss business hubs all over the world. In China, its

瑞士是欧洲最大的生命科学中心和生物技术和药物研究的顶级场所。成千上万的科学家、世界一流的研究机构（如苏黎世联邦理工学院、巴塞尔大学或保罗谢尔研究所）和生命科学领域1,500多家公司构成了一个独特的创新生态系统，为全球顶级制药产业集群之一。PARK INNOVAARE是进入该生态系统的完美入口。

谁应考虑搬迁到PARK INNOVAARE?

对于希望改进药物开发过程早期阶段的公司，PARK INNOVAARE为首选之地。保罗谢尔研究所（PSI）拥有独特的大型综合研究设施，在深入了解分子结构及其相互作用方面得天独厚。众多专业服务提供者为制药和生物技术公司提供最佳样品分析结果，是可靠的研究合作伙伴。

如何启动搬迁程序?

请联系我们! 我们了解您的需求后，将让您接触各领域的首席科学家或公司决策者，帮助您发现场地的现有机会。我们还与当地推广机构的专家合作，提供税务和法律事务咨询服务。

在哪里可以看到有关瑞士现有机会的更多信息?

瑞士有一个高度服务导向型外贸促进机构，即Swiss Global Enterprise（S-GE），在全世界拥有瑞士商业中心。中国办事处位于北京、上海和广州。您可以联系他们或直接与首选的瑞士研究机构联系。PARK INNOVAARE和保罗谢尔研究所（PSI）进行过1,000多次行业合作，在成功推动公司研发项目方面经验丰富。

offices are situated in Beijing, Shanghai and Guangzhou. You can contact them or directly reach out to the preferred research institution in Switzerland. PARK INNOVAARE and the Paul Scherrer Institute (PSI), with its more than 1,000 industrial collaborations, have vast experience in supporting companies driving their R&D projects to success.

What else may be of interest?

At PARK INNOVAARE, as well as at the other five locations of Switzerland Innovation, you will find a large community of highly dynamic start-ups and very promising spin-offs. Many of them are open to foreign investments.

还有其他值得关注的吗?

在PARK INNOVAARE，以及瑞士其他五个创新场所，您将发现大量开始创业的公司和脱离母公司后非常有前途的公司。其中许多公司对外商投资持开放态度。

Partners 合作伙伴:

PAUL SCHERRER INSTITUT PSI

KANTON AARGAU

HIGHTECH ZENTRUM AARGAU

n|w Fachhochschule Nordwestschweiz

TECHNOPARK® AARGAU

Do you want to know more ? Reach out to us !
想了解更多? 请与我们联系!

Francesco Colonna, PhD
Senior Project Manager
Innovation & Funding
高级创新资金项目经理
colonna@parkinnovaare.ch

Nils Gebhardt, M.A. / MBA
Managing Director
总经理
gebhardt@parkinnovaare.ch

SWITZERLAND
INNOVATION
PARK INNOVAARE

innovAARE AG

PARK INNOVAARE: deliveryLAB
5234 Villigen
Switzerland
+41 56 461 70 70
info@parkinnovaare.ch
www.parkinnovaare.ch
#WhereInnovationAccelerates